Neoadjuvant docetaxel and capecitabine (TX) versus docetaxel and epirubicin (TE) for locally advanced or early her2-negative breast cancer: an open-label, randomized, multi-center, phase II Trial

PURPOSE: The combination of taxanes and anthracyclines is still the mainstay of chemotherapy for early breast cancer. Capecitabine is an active drug with a favorable toxicity profile, showing strong anti-tumor activity against metastatic breast cancer. This trial assessed the efficacy and safety of...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Houpu, Xu, Ling, Guan, Shan, Hao, Xiaopeng, Ge, Zhicheng, Tong, Fuzhong, Cao, Yingming, Liu, Peng, Zhou, Bo, Cheng, Lin, Liu, Miao, Liu, Hongjun, Xie, Fei, Wang, Siyuan, Peng, Yuan, Wang, Chaobin, Wang, Shu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795638/
https://www.ncbi.nlm.nih.gov/pubmed/36577958
http://dx.doi.org/10.1186/s12885-022-10439-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795638/
https://www.ncbi.nlm.nih.gov/pubmed/36577958
http://dx.doi.org/10.1186/s12885-022-10439-0

Ejemplares similares